Nuburu Drops to OTC Pink After 1-for-40 Reverse Split, NYSE Appeal Underway

What happened

Nuburu announced a 1-for-40 reverse stock split and began trading on OTC Pink under temporary symbol BURUD, a clear signal it lost its NYSE American listing and is now appealing. The move follows months of compliance struggles; as of March 31, 2026, stockholders' equity was only $2.17 million, below the $4 million NYSE requirement, and the company had until October 29, 2026 to cure. The reverse split was intended to address share price, but the equity deficiency likely persists, and trading on OTC Pink reduces institutional interest and liquidity. Management's shareholder letter frames the move as part of strategic progress, but it underscores that the company's financing and listing risks have materialized. With only $0.48 million pro forma quarterly revenue and ongoing going-concern doubts, the move to OTC further weakens the investment case.

Implication

In the near term, the shift to OTC Pink impairs Nuburu's ability to raise capital through the equity markets, making discounted financings more likely and increasing dilution risk. The company's appeal to NYSE American may take months, and without a clear path to regain compliance, institutional support will continue to erode. Even if the appeal succeeds, the company still faces the unresolved Tekne acquisition, Golden Power approval, and the need to demonstrate operating progress. The master report's WAIT rating was contingent on NYSE compliance by October 29, 2026; that condition is now breached, suggesting a downgrade to SELL or AVOID. Longer-term, the company's survival depends on closing Tekne and generating revenue, but the OTC listing reduces transparency and investor confidence, making that task even harder.

Thesis delta

The thesis has shifted from a conditional WAIT to a more bearish stance. The reverse split and OTC listing indicate the company failed to meet NYSE American requirements, breaching a key condition for the prior investment case. The probability of near-term financing and strategic success has decreased, moving the risk-reward from balanced to unfavorable, and fair value is now likely closer to the bear case of $0.06 or lower.